Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?

Creative Commons License

TAÇYILDIZ N., Tanyildiz H. G., DİNÇASLAN H., Yavuz G., ÜNAL E., ÖZKAN E., ...Daha Fazla

IRANIAN JOURNAL OF PEDIATRICS, cilt.26, sa.2, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5812/ijp.4008
  • Dergi Adı: IRANIAN JOURNAL OF PEDIATRICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Bone Tumors, Sorafenib, Anti-VEGF, PET, REFRACTORY SOLID TUMORS, PHASE-I TRIAL, ONCOLOGY GROUP, MURAMYL TRIPEPTIDE, PEDIATRIC-PATIENTS, EWING SARCOMA, F-18-FDG PET, OSTEOSARCOMA, DIFFERENTIATION, TEMOZOLOMIDE
  • Ankara Üniversitesi Adresli: Evet

Özet

Background: The prognosis is still poor for patients with a metastatic bone tumor and new treatment approaches (anti-VEGF and tyrosine kinase inhibitors vs) are therefore needed.